Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 2,601–2,700 of 4,108
Gerber, L. M., & Madimenos, F. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-44103-0_12 · Cited by 4
Medical Cost Analysis of the Osteoporotic Hip Fractures
Çamur, S., Kılınç, B. E., Sönmez, M. M., Çelik, H., & Öç, Y. (2015) · Turkish Journal of Osteoporosis · doi:10.4274/tod.83702 · Cited by 3
Wandurraga-Sánchez, E. A., Carrillo, L. F. M., Melo, A. K. N., et al. (2017) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.3.4.5 · Cited by 3
Sears, R. (2020) · JAAPA · doi:10.1097/01.jaa.0000662384.93538.a2 · Cited by 3
Vidal, M., & Lane, N. E. (2020) · Rheumatology and Orthopedic Medicine · doi:10.15761/rom.1000171 · Cited by 4
Analysis of serum bone turnover markers in female cynomolgus monkeys of different ages
Li, Y., Cai, Q., Dong, C., Hou, L., Li, Y., Guo, B., Zeng, C., Cheng, Y., Shang, J., Ling, X., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.984523 · Cited by 5
“It is, together with PINP, a reference marker for bone formation and bone resorption internationally recognized by the IOF (International Frontiers in Endocrinology 02 Osteoporosis Foundation) and IFCC (International Federation Of Clinical Chemistry And Labora-Tory Medicine) (12).”
BackgroundIreland DXA-FRAX may differ significantly and substantially to Web-FRAX
Yang, L., Dempsey, M., Brennan, A., Whelan, B., Erjiang, E., Wang, T., Egan, R., Gorham, K., Heaney, F., Armstrong, C., et al. (2023) · Archives of Osteoporosis · doi:10.1007/s11657-023-01232-y · Cited by 3
“Substantial efforts over many years supported the development of the FRAX tool such that it has become the dominant fracture risk assessment tool worldwide [26] and is the preferred algorithm of global professional bodies in skeletal health [2, 3, 26–29].”
BackgroundMethodErden, E., Türk, A. Ç., Fidan, N., & Erden, E. (2023) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2023.101428 · Cited by 3
Nagata, K., Dimar, J. R., Carreon, L. Y., & Glassman, S. D. (2023) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2023.06.015 · Cited by 3
Jödicke, A., Tan, E. H., Robinson, D. E., Delmestri, A., & Prieto-Alhambra, D. (2023) · Age and Ageing · doi:10.1093/ageing/afad177 · Cited by 3
“General practitioner visits, 1 yr 11 [7, 18] 11 [6, 17] 11 [7, 18]”
BackgroundBailey, S., & Fraser, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1229796 · Cited by 9
GENDER IDENTIFICATION FROM LEFT HAND-WRIST X-RAY IMAGES WITH A HYBRID DEEP LEARNING METHOD
Özdemir, C., Gedik, M. A., Küçüker, H., & Kaya, Y. (2023) · Konya Journal of Engineering Sciences · doi:10.36306/konjes.1294139 · Cited by 4
Fu, S., Lai, C. Y., Wang, C.-Y., Hung, C.-C., Ye, J.-D., Yen, H., Wu, C.-H., Ku, L. E., Yu, T.-T., Yang, R., et al. (2023) · The journal of nutrition health & aging · doi:10.1007/s12603-023-2045-3 · Cited by 4
The association of the Affordable Care Act with nutrient consumption in adults in the United States
Kirk, H. M., Tufuor, T. A., Shaver, A. L., Nie, J., Devarshi, P. P., Marshall, K., Mitmesser, S. H., & Noyes, K. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1244042 · Cited by 3
Aguado, H. J., Mingo-Robinet, J., García-Virto, V., et al. (2023) · Injury · doi:10.1016/j.injury.2023.111043 · Cited by 3
Xu, F., Wang, Y., & Zhu, X. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.12.010 · Cited by 4
Anti-osteoporotic effects of Yi Mai Jian on bone metabolism of ovariectomized rats
Shi, B., Lin, C.-C., Lee, C., Deshan, N., Lin, C.-C., Zhao, H., Yang, C.-S., Deng, S.-X., Chiu, Y., & Wang, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1326415 · Cited by 3
Pinto-Bonilla, R., Baeza-Noci, J., Blanco, C. C., Gumbau, G. J. V., Fernández, R. J., Pascual-Pastor, M., Magallón, B. G., Lamothe, B. P., Moragues, C., Aviñó, R. I., et al. (2024) · Bone Reports · doi:10.1016/j.bonr.2024.101796 · Cited by 4
“…high doses within the interval recommended by guidelines (800 – 2000 IU) (Casado et al., 2021; Camacho et al., 2020; Naranjo Hernandez et al., 2019; Presa Lorite et al., 2022; Holick et al., 2011; Dawson-Hughes et al., 2010; Cosman et al., 2014; Aspray et al., 2014; Baixauli García et al., 2022).”
BackgroundSalis, Z. (2024) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.15279 · Cited by 3
“18 Bisphosphonate non-users were those who reported no use in the 5 years preceding the baseline and at any sub - sequent follow-up.”
Kawai, Y., Uneda, K., Miyata, S., Kunii, A., Nagayama, S., Baba, K., & Iwamoto, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-72505-w · Cited by 4
A Causal Inference Methodology to Support Research on Osteopenia for Breast Cancer Patients
Kiriakidou, N., Ballas, A., Hernándo, C., Miralles-Marco, A., Stamati, T., Anagnostopoulos, D., & Diou, C. (2024) · Applied Sciences · doi:10.3390/app14219700 · Cited by 4
Arrebola, M. M., Filella, X., Albaladejo-Otón, M. D., Giménez, N., Olmedo, M., García-Martínez, R. J., Estruch, E. B., Santamaría-González, M., Pérez-Torrella, D., Morell‐García, D., et al. (2024) · PubMed Central · Cited by 7
Yodkhunnatham, N., Riviere, P. J., Pandit, K. M., Morgan, K. M., Meagher, M. F., Dabbas, M., Nelson, T. J., Puri, D., Yuen, K., Taylor, J., et al. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102332 · Cited by 3
Gibbons, B., Lubsen, J., & Martonffy, A. I. (2025) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2025.01.008 · Cited by 3
Gleich, J., Steiner, E., Ehrnthaller, C., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103346 · Cited by 3
Köroğlu, E. Y., Ogmen, B. E., Balsak, B. Ö. T., et al. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2506983 · Cited by 3
“The criteria of the World Health Organization have been used in interpreting DEXA-BMD results [12].”
Comprehensive Analysis of the Role of Metabolic Features in Osteoporosis: A Multi-Omics Analysis
Chang, S., Tao, W., Shi, P., Wu, H., Liu, H., Xu, J., Chen, J., & Zhu, J. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s515717 · Cited by 3
The Validation of an Experimental Model in Wistar Female Rats to Study Osteopenia and Osteoporosis
Pedroso, A. L., Canal, R., Gehrke, S. A., da Costa, E. M., Scarano, A., Zanelatto, F. B., & Pelegrine, A. A. (2025) · Bioengineering · doi:10.3390/bioengineering12070702 · Cited by 7
“…density − average GC/Standard Deviation of GC. Based on the T-score results, the conditions were categorized, assigning a normal status when the T-score was above − 1.0, a condition of osteopenia when the T-score varied between − 1.0 and − 2.5, and osteoporosis when the T-score was below − 2.5 [1].”
InfluentialZaheer, M. H., Zaheer, H., & Tariq, A. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf121 · Cited by 3
“15 Nevertheless, the continued upward trend—though not statistically significant—indicates that vertebral fracture-related mortality remains a persistent clinical challenge.”
Multidisciplinary consensus on the management of patients with osteopenia and fracture risk in Spain
Úbeda, J. L. B., Díaz, S. G., Martínez, J. C. G., Martínez, N., Micó-Pérez, R. M., Möller, I., Neyro, J. L., Sáez-López, P., Santiñà, M., Vergés, J., et al. (2025) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-025-08997-y · Cited by 5
“Activities like daily walking for at least 30 min and balance-focused practices such as yoga, tai chi, and Pilates are strongly recommended [47–49].”
Current Medical Therapies for Osteoporosis and Its Alternative Treatments Using Natural Products
Oh, S., & Ahn, S. (2015) · Journal of Life Science · doi:10.5352/jls.2015.25.1.113 · Cited by 3
Access to Oral Osteoporosis Drugs Among Female Medicare Part D Beneficiaries
Lin, C.-W., Karaca‐Mandic, P., McCullough, J. S., & Weaver, L. (2014) · Women s Health Issues · doi:10.1016/j.whi.2014.04.002 · Cited by 3
Bone Density and Bone Turnover Marker Monitoring After Discontinuation of Alendronate Therapy
Gourlay, M. L., & Ensrud, K. E. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.162 · Cited by 3
Casas-Ávila, L., Valdés‐Flores, M., Miranda‐Duarte, A., et al. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1092511 · Cited by 3
Borgelt, L. M., Kostoff, M., & Saseen, J. J. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s57549 · Cited by 3
Bellefqih, S., Hadadi, K., Mezouri, I., Maghous, A., Marnouche, E., Andaloussi, K., Elmarjany, M., Sifat, H., Mansouri, H., & Benjaafar, N. (2016) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2015.12.002 · Cited by 3
Estrogen and Estrogen Analogs for Prevention and Treatment of Osteoporosis
Gass, M. L. S., & Khan, S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00077-7 · Cited by 3
Patient and Provider Characteristics Associated With Optimal Post-Fracture Osteoporosis Management
Boytsov, N. N., Crawford, A. G., Hazel-Fernandez, L. A., McAna, J. F., Nair, R., Saundankar, V., Varga, Š., & Yang, F. E. (2017) · American Journal of Medical Quality · doi:10.1177/1062860617691123 · Cited by 3
on behalf of the PAADRN Investigators, Wolinsky, F. D., Lou, Y., Edmonds, S. W., Saag, K. G., Roblin, D. W., Wright, N. C., Jones, M., & Cram, P. M. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4101-5 · Cited by 3
Low-dose diclofenac in patients with fragility fractures.
Vannucci, L., Fossi, C., Gronchi, G., & Brandi, M. (2017) · CLINICAL CASES IN MINERAL AND BONE METABOLISM · doi:10.11138/ccmbm/2017.14.1.015 · Cited by 3
Fragility Fractures of the Pelvis: New Approaches to Classification and Management
Gupta, P., Lenchik, L., Bawa, P., & Wuertzer, S. D. (2017) · Current Radiology Reports · doi:10.1007/s40134-017-0259-z · Cited by 4
Imaging in Clinical and Preclinical Practice
Petrović, S., & Korunović, N. (2017) · Springer eBooks · doi:10.1007/978-3-319-68025-5_20 · Cited by 3
Kaboré, N. F., Eymard‐Duvernay, S., Zoungrana, J., Badiou, S., Bado, G., Héma, A., Diouf, A., Delaporte, É., Koulla‐Shiro, S., Ciaffi, L., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186686 · Cited by 4
de Almeida, D. O., Araújo, E. M. Q., & Lemaire, D. C. (2017) · Revista de Ciências Médicas e Biológicas · doi:10.9771/cmbio.v16i3.24384 · Cited by 3
Consensus document on osteoporosis in males
Varsavsky, M., Muñoz, M. R., Rubio, V. Á., Becerra, A., Martín, A. G., Diaz‐Guerra, G. M., Moreno, P. R., Gimeno, E. J., & Muñoz‐Torres, M. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2017.12.003 · Cited by 5
Mousavi, M., Zadeh, A., Hanafi, M., et al. (2019) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_456_18 · Cited by 3
Liu, X., Choudhury, A., & Anderson, C. (2019) · PubMed Central · Cited by 3
Endocrinological Features of Hartsfield Syndrome in an Adult Patient With a Novel Mutation of FGFR1
Kobayashi, S., Tanigawa, J., Kondo, H., Nabatame, S., Maruoka, A., Sho, H., Tanikawa, K., Inui, R., Otsuki, M., Shimomura, I., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa041 · Cited by 3
How Should We Counsel Asian Americans about Fracture Risk?
Lo, J. C.-M., & Ettinger, B. B. (2020) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16444 · Cited by 3
“The most widely use fracture risk calculator is FRAX (http://www.shef.ac.uk/ FRAX; accessed March 1, 2020), which integrates femoral neck BMD and clinical risk factors to calculate 10-year probability estimates of hip and any one of four major osteoporotic fractures for whites, blacks, Hispanics, and Asians.6 As FRAX…”
BackgroundInfluentialKılınçarslan, M. G., Şahin, E. M., Sarıgül, B., & KOCAOĞLU, S. B. (2020) · Turkish Journal of Osteoporosis · doi:10.4274/tod.galenos.2019.07269 · Cited by 3
Rao, M., & Awasthi, M. (2020) · AIMS Medical Science · doi:10.3934/medsci.2020015 · Cited by 3
Itoi, E., Uemura, Y., Ohta, H., Nakamura, T., Fukunaga, M., Orimo, H., & Shiraki, M. (2020) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2020.10.017 · Cited by 4
Actividades preventivas en la mujer. Actualización PAPPS 2020
García‐Franco, A. L., Fernández, J. A. B., Muñoz, E. B., Piñeiro, M. J. I., del Moral, A. O., Alonso‐Coello, P., Cabello, C. R., Goñi, J. L., & Mir, L. A. (2020) · Atención Primaria · doi:10.1016/j.aprim.2020.09.001 · Cited by 7
Bifunctional Role of CrkL during Bone Remodeling
Kim, J. H., Kim, K., Kim, I., Seong, S., Kook, H. Y., Kim, K. K., Koh, J., & Kim, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137007 · Cited by 4
Miranda, C., de Morais, V. F. B., Martins, F. M., Pelet, D. C. S., Orsatti, C. L., Cangussu, L. M., Nahás, E. A. P., Santagnello, S. B., de Paula, R. F., Souza, M. V. C., et al. (2021) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001820 · Cited by 3
Huo, Z., Liu, X., Yong-feng, W., Liang, Y., Xu, R., Ma, Y., Li, S., Shen, J., & Tang, X. (2021) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2021.1952484 · Cited by 3
Treat-to-Target in Osteoporosis
Miedany, Y. M. E., & Bahlas, S. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-87950-1_18 · Cited by 3
Rabah, D. M., Alkhateeb, S., Abusamra, A. J., Alotaibi, M., Mahmood, R. I., Al-Mansour, M. M., Murshid, E., Alsharm, A. A., Alolayan, A. A. M., Ahmad, I., et al. (2014) · Urology Annals · doi:10.4103/0974-7796.140959 · Cited by 3
Late Effects of Allogeneic Hematopoietic Stem Cell Transplantation in an Asian Patient Population
Fong, C. M., Jiun, Y., & Yen, N. H. (2021) · BLOOD CELL THERAPY / The official journal of APBMT · doi:10.31547/bct-2020-020 · Cited by 2
Yu, S., Chen, J., Chen, Y., Wang, Y., Hsu, C., Lai, H., He, H.-R., Ko, C., Chiu, W.-C., & Cheng, T. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.885801 · Cited by 4
“5 or less at the FN based on the normal reference database for young white females (15, 16).”
BackgroundAypak, C., Bircan, M. A., & Özdemir, A. (2022) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10473 · Cited by 3
Morkos, M., Mahrous, P., Casagrande, A., Go, M. T., Husni, H., Hanna, M., Goel, M., Bedrose, S. S. D., Li, D., & Baim, S. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.06.011 · Cited by 3
Dinçel, Y. M., Can, E., Amiry, M., Genç, E., Çağlar, S., Morina, M., & Kaval, B. (2022) · Turkish Journal of Osteoporosis · doi:10.4274/tod.galenos.2021.80488 · Cited by 3
Bone pathology in chronic kidney disease
Karlovich, N., Mokhort, T. V., & Sazonava, A. G. (2022) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12943 · Cited by 4
Guillaumin, M., Poirson, B., Gerazime, A., Puyraveau, M., Tannou, T., Mauny, F., & Toussirot, É. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.845886 · Cited by 3
“Osteoporosis is a skeletal systemic disease characterized by a reduction in bone mass and bone mineral density (BMD), deterioration of the bone micro-architecture, and a subsequent increase in the risk of fracture of the spine, hip and other sites (Kanis et al., 2013; Cosman et al., 2014; Black and Rosen, 2016).”
BackgroundNoble, A. J., Mason, S. M., Bonnett, L. J., Reuber, M., Wright, J., Pilbery, R., Jacques, R., Simpson, R. M., Campbell, R., Fuller, A., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-069156 · Cited by 4
Hypocalcemia Is a Common Risk Factor for Osteoporosis in Taiwanese Patients with Cushing’s Syndrome
Chen, Y., Tsai, J., Chen, J., & Shen, F. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192316064 · Cited by 4
“The National Osteoporosis Foundation (NOF) recommended calcium consumption of 1000 mg/day for men aged 50–70 years and 1200 mg/day of calcium for women older than 51 years and men older than 71 years [21].”
BackgroundEffect of resistance exercise on bone health of old aged individuals: Review
Khanna, A. (2022) · Science & Sports · doi:10.1016/j.scispo.2022.09.003 · Cited by 6
Yuan, N., Wang, X., & He, M.-H. (2023) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2023.152070 · Cited by 3
Interaction of Metals, Menopause and COVID-19—A Review of the Literature
Męcik-Kronenberg, T., Kuć, A. J., Kubik-Machura, D., Kościelecka, K. E., & Radko, L. (2023) · Biology · doi:10.3390/biology12030350 · Cited by 4
“In the skeletal system, in turn, it lowers bone mineral density, leading to osteoporosis [6,7,38].”
Feder, D., Mohd-Pahmi, S. H., Adibi, H., Guddat, L. W., Schenk, G., McGeary, R. P., & Hussein, W. M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115383 · Cited by 3
A retrospective analysis of nonresponse to denosumab after hip fractures
KIM, S.-J., & LEE, D.-W. (2023) · Acta Orthopaedica Belgica · doi:10.52628/89.1.9808 · Cited by 4
A novel primary osteoporosis screening tool (POST) for adults aged 50 years and over
Tang, Y., Liu, J., Tian, C., Feng, Z., Zhang, X., Xia, Y., & Geng, B. (2023) · Endocrine · doi:10.1007/s12020-023-03442-3 · Cited by 3
Herbal Remedies for Osteoporosis
Mahant, M., Besh, S. B., Kanojiya, D., Sajan, C., Rajput, H. S., & Maheshwari, R. A. (2023) · Journal of Natural Remedies · doi:10.18311/jnr/2023/34056 · Cited by 4
Kim, S., Jang, S.-H., & Lee, O. (2023) · Microscopy Research and Technique · doi:10.1002/jemt.24457 · Cited by 3
“When bone density decreases, the risk of fracture increases, which can lead to secondary complications (Bergland et al., 2011; Cosman et al., 2014; Sambrook & Cooper, 2006).”
BackgroundLee, S. H., Kim, J. S., & Koh, J. (2023) · Journal of Bone Metabolism · doi:10.11005/jbm.2023.30.4.355 · Cited by 4
Yu, Y., Huang, Q., An, D., Raad, J., Martens, D. S., Latosińska, A., Stolarz‐Skrzypek, K., Cleemput, J. V., Feng, Y., Mischak, H., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24867 · Cited by 3
“BMD testing by dual energy XRA is consensually the gold standard in the diagnosis and management of osteoporosis, because the so-determined BMD at the lumbar spine and hip closely correlates with bone strength and is an excellent predictor of future fracture risk [13,14].”
BackgroundMethodInfluentialTreatment Strategies in the Osteoporotic Spine
Gelvez, D., Dong, K., Redlich, N. J., et al. (2024) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2024.01.001 · Cited by 3
Sucharitpongpan, W. (2024) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2023.12.004 · Cited by 3
“…the risk factors: age, gender, body mass index (BMI), history of bone fragility fractures, family history of HF, smoking, prolonged use of corticosteroids, rheumatoid arthritis, other causes of secondary osteoporosis and high alcohol consumption in combination with bone mineral density (BMD) [6,7].”
BackgroundAssari, A. S., Alanazi, Y., Algharbi, E. M., et al. (2024) · Cureus · doi:10.7759/cureus.52896 · Cited by 3
Uzeli, Ü. Ş., & Doğan, M. (2024) · Journal of Orthopedics Research and Rehabilitation · doi:10.51271/jorr-0023 · Cited by 3
Visual scoring of osteoporosis on low-dose CT in lung cancer screening population
Zhu, Y., Yip, R., Jirapatnakul, A. C., Huang, M., Cai, Q., Dayan, E., Liu, L., Reeves, A. P., Henschke, C. I., & Yankelevitz, D. F. (2024) · Clinical Imaging · doi:10.1016/j.clinimag.2024.110115 · Cited by 3
Miyamoto, A., Parihar, U., Kumawat, C., et al. (2024) · Medicina · doi:10.3390/medicina60040519 · Cited by 3
“Some studies suggest a conservative treatment effort lasting two to three weeks, while others offer no advice at all about time [28,29].”
BackgroundInfluence of Osteoporosis on the Course of Apical Periodontitis
Stanev, E., & Vassileva, R. (2024) · European Journal of Dentistry · doi:10.1055/s-0044-1785533 · Cited by 3
Mostafa, S. M., Elebrashy, I., Haddad, H. E. E., Shaker, O. G., Razek, N. M. A., & Fayed, A. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01388-8 · Cited by 6
Zhao, A. S., Liu, Y., Mulvey, J. J., & Tchang, B. G. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07243-w · Cited by 3
“Since expert guidelines currently recommend bisphosphonates as first-line options in most cases of osteoporosis [37–39], the future of combination therapy may be niched to severe osteoporosis where anabolics are the preferred first agent, as in very high-risk GIO [40].”
Stojšić, K., Rigo, D. M., & Jurković, S. (2024) · Applied Sciences · doi:10.3390/app142210343 · Cited by 5
Ahn, T. R., Lee, J. H., & Lee, J.-B. (2024) · Scientific Reports · doi:10.1038/s41598-024-79985-w · Cited by 3
Wong, A. K. O., Pokhoy, A., Naraghi, A., & Mohankumar, R. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01517-4 · Cited by 3
“According to the World Health Organization, these individuals with 10-year fracture probability ≥ 20% require osteoporosis treatment [27].”
A practical use of bone turnover markers in management of patients with skeletal fragility
Brunetti, A., Cellini, M., Vitale, V., Gentile, L. M. S., Birtolo, M. F., Vescini, F., Lania, A. G., & Mazziotti, G. (2025) · Endocrine · doi:10.1007/s12020-025-04275-y · Cited by 6
“In patients treated with bisphosphonates, a “ drug holiday ” may be considered after at least fi ve years of treatment with alendronate or three years of zoledronate [55, 56].”
Cost‑effectiveness analysis of fracture liaison services in Iran
Mousavi, A., Daroudi, R., Fahimfar, N., et al. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01555-y · Cited by 3
“According to the WHO diagnostic classification, “osteoporosis is defined by BMD at the hip or lumbar spine that is less than or equal to 2.5 standard deviations below the mean BMD of a young-adult reference popula-tion” [2].”
InfluentialBlümke, A., Okoro, A. C. C. E. B. U., Pinheiro, J., Mellinghoff, M., Kühlwein, D., Vadgaonkar, A., Bludau, F., Schilder, A., Hetjens, S., Hackl, M., et al. (2025) · BMC Research Notes · doi:10.1186/s13104-025-07400-2 · Cited by 4
“Classifications were made according to the current recommendations of the National Osteoporosis Foundation (NOF) and relevant literature [12, 13].”
Screening Tests for Osteoporosis: Too Few for Some, Too Many for Others
Bauer, D. C. (2015) · Journal of General Internal Medicine · doi:10.1007/s11606-015-3446-8 · Cited by 3
An Unusual Adverse Event from a Common Medication in an Individual with Dementia
Casiano, V. E., Kalish, V. B., & Unwin, B. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13078 · Cited by 3
Wright, D. H., Mols, R., Brown, K. R., et al. (2015) · Current Therapeutic Research · doi:10.1016/j.curtheres.2015.10.001 · Cited by 3
del Pino‐Montes, J., Blanch‐Rubió, J., Nogués, X., Moro, M. J., Valero, C., Canals, L., & Lizán, L. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0314-9 · Cited by 5
The Investigation of the Awareness of Osteoporosis in Postmenopausal Women
Ahmet, E. (2017) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/2455-8583.000028 · Cited by 3
Vitamin D yetersizliği ve eksikliğine güncel yaklaşım
Doğan, M., & DOĞAN, A. G. (2019) · Journal of Health Sciences and Medicine · doi:10.32322/jhsm.496326 · Cited by 3
Агранович, Н. В., Сергеевна, А. А., Пилипович, Л. А., et al. (2019) · Problems of Balneology Physiotherapy and Exercise Therapy · doi:10.17116/kurort2019960114 · Cited by 3
Vitamin D im Alter: Ist der Hype definitiv vorüber?
Bischoff-Ferrari, H. A. (2019) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0851-9737 · Cited by 4
“Insbesondere für ältere Erwachsene mit einem erhöhten Risiko für Frakturen und/oder Vitamin-D-Mangel ist es weiterhin sinnvoll, 800 bis 1000 IE Vitamin D pro Tag einzunehmen, analog den Empfehlungen der International Osteoporosis Foundation [19], der US Endocrine Society [20] und NOF [21].”
Background
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.